AP2005003283A0 - Indole derivatives useful for the treatment os diseases - Google Patents

Indole derivatives useful for the treatment os diseases

Info

Publication number
AP2005003283A0
AP2005003283A0 AP2005003283A AP2005003283A AP2005003283A0 AP 2005003283 A0 AP2005003283 A0 AP 2005003283A0 AP 2005003283 A AP2005003283 A AP 2005003283A AP 2005003283 A AP2005003283 A AP 2005003283A AP 2005003283 A0 AP2005003283 A0 AP 2005003283A0
Authority
AP
ARIPO
Prior art keywords
diseases
treatment
indole derivatives
derivatives useful
useful
Prior art date
Application number
AP2005003283A
Other languages
English (en)
Inventor
Alan Daniel Brown
Mark Edward Et Al Bunnage
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20020292513 external-priority patent/EP1407769A1/en
Priority claimed from EP03290069A external-priority patent/EP1440966A1/en
Application filed by Pfizer filed Critical Pfizer
Publication of AP2005003283A0 publication Critical patent/AP2005003283A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AP2005003283A 2002-10-11 2003-10-06 Indole derivatives useful for the treatment os diseases AP2005003283A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20020292513 EP1407769A1 (en) 2002-10-11 2002-10-11 Indole derivatives as beta-2 agonists
EP03290069A EP1440966A1 (en) 2003-01-10 2003-01-10 Indole derivatives useful for the treatment of diseases
PCT/IB2003/004441 WO2004032921A1 (en) 2002-10-11 2003-10-06 Indole derivatives as beta-2 agonists

Publications (1)

Publication Number Publication Date
AP2005003283A0 true AP2005003283A0 (en) 2005-06-30

Family

ID=32095049

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003283A AP2005003283A0 (en) 2002-10-11 2003-10-06 Indole derivatives useful for the treatment os diseases

Country Status (25)

Country Link
EP (1) EP1556034B1 (xx)
JP (1) JP4490911B2 (xx)
KR (1) KR20050047552A (xx)
AP (1) AP2005003283A0 (xx)
AR (1) AR041566A1 (xx)
AT (1) ATE392206T1 (xx)
AU (1) AU2003269316A1 (xx)
BR (1) BR0315234A (xx)
CA (1) CA2499314C (xx)
CO (1) CO5550421A2 (xx)
DE (1) DE60320439T2 (xx)
EA (1) EA200500618A1 (xx)
EC (1) ECSP055780A (xx)
ES (1) ES2302938T3 (xx)
IS (1) IS7751A (xx)
MA (1) MA27452A1 (xx)
MX (1) MXPA05003866A (xx)
NO (1) NO20051406L (xx)
OA (1) OA12938A (xx)
PA (1) PA8586001A1 (xx)
PE (1) PE20040775A1 (xx)
PL (1) PL376396A1 (xx)
TW (1) TW200424171A (xx)
UY (1) UY28013A1 (xx)
WO (1) WO2004032921A1 (xx)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
EP1460064A1 (en) * 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
GB0312832D0 (en) * 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
WO2005092841A1 (en) * 2004-03-23 2005-10-06 Pfizer Limited Compounds having beta-agonist activity
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
KR20080036632A (ko) 2005-08-08 2008-04-28 아젠터 디스커버리 리미티드 바이시클로[2.2.1]헵트-7-일아민 유도체 및 이들의 용도
CA2625664C (en) 2005-10-21 2016-01-05 Novartis Ag Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
MEP9608A (en) 2006-03-20 2010-06-10 Pfizer Ltd Amine derivatives
US8258141B2 (en) 2006-04-21 2012-09-04 Novartis Ag Organic compounds
CN101553493B (zh) 2006-07-19 2012-07-04 阿斯利康(瑞典)有限公司 三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
CN101610813A (zh) 2006-12-19 2009-12-23 阿斯利康(瑞典)有限公司 作为毒蕈碱受体拮抗剂的奎核醇衍生物
DK2104535T3 (da) 2007-01-10 2011-04-04 Irm Llc Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer
AU2008214214B2 (en) 2007-02-09 2011-09-15 Irm Llc Compounds and compositions as channel activating protease inhibitors
PL2155721T3 (pl) 2007-05-07 2011-07-29 Novartis Ag Związki organiczne
PE20091096A1 (es) 2007-12-10 2009-08-25 Novartis Ag Compuestos organicos
KR20100113557A (ko) 2008-01-11 2010-10-21 노파르티스 아게 키나제 억제제로서의 피리미딘
NZ589091A (en) 2008-05-13 2011-07-29 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
RU2509077C2 (ru) 2008-05-27 2014-03-10 Астразенека Аб Феноксипиридиниламидные производные и их применение в лечении pde4-опосредованных болезненных состояний
BRPI0915018A2 (pt) 2008-06-10 2015-10-27 Novartis Ag compostos orgânicos
US8236786B2 (en) 2008-08-07 2012-08-07 Pulmagen Therapeutics (Inflammation) Limited Respiratory disease treatment
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
PT2379507E (pt) 2008-12-30 2014-01-21 Pulmagen Therapeutics Inflammation Ltd Compostos de sulfonamida para o tratamento de desordens respiratórias
WO2010150014A1 (en) 2009-06-24 2010-12-29 Pulmagen Therapeutics (Inflammation) Limited 5r- 5 -deuterated glitazones for respiratory disease treatment
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CN102665715A (zh) 2009-10-22 2012-09-12 沃泰克斯药物股份有限公司 治疗囊性纤维化和其他慢性疾病的组合物
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011098746A1 (en) 2010-02-09 2011-08-18 Pulmagen Therapeutics (Inflammation) Limited Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone
GB201002224D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
GB201002243D0 (en) 2010-02-10 2010-03-31 Argenta Therapeutics Ltd Respiratory disease treatment
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
PE20140378A1 (es) 2011-02-25 2014-03-28 Irm Llc Compuestos y composiciones como inhibidores de la trk
AR085509A1 (es) 2011-03-09 2013-10-09 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
ES2552538T3 (es) 2011-06-10 2015-11-30 Chiesi Farmaceutici S.P.A. Compuestos que tienen una actividad antagonista de un receptor muscarínico y agonista de un receptor beta-2 adrenérgico
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2013038386A1 (en) 2011-09-16 2013-03-21 Novartis Ag Heterocyclic compounds for the treatment of cystic fibrosis
JP6165733B2 (ja) 2011-09-16 2017-07-19 ノバルティス アーゲー Ｎ−置換ヘテロシクリルカルボキサミド類
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
KR102156441B1 (ko) 2012-12-06 2020-09-17 키에시 파르마슈티시 엣스. 피. 에이. 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물
SG10201704032RA (en) 2012-12-06 2017-06-29 Chiesi Farm Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
AR099336A1 (es) 2014-02-17 2016-07-13 Bayer Cropscience Ag Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas
CN106458980A (zh) 2014-04-24 2017-02-22 诺华股份有限公司 作为磷脂酰肌醇3‑激酶抑制剂的氨基吡啶衍生物
MX2016013812A (es) 2014-04-24 2017-03-09 Novartis Ag Derivados de amino-pirazina como inhibidores de fosfatidil-inositol-3-cinasa.
CN106458966B (zh) 2014-04-24 2019-05-07 诺华股份有限公司 作为磷脂酰肌醇3-激酶抑制剂的吡嗪衍生物
CA3139634A1 (en) 2019-06-10 2020-12-17 Novartis Ag Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CN114341132A (zh) 2019-08-28 2022-04-12 诺华股份有限公司 经取代的1,3-苯基杂芳基衍生物及其在治疗疾病中的用途
AU2021296221A1 (en) 2020-06-26 2023-02-02 Mylan Pharma Uk Limited Formulations including 5-(3-(3-hydroxyphenoxy)azetidin-1-yl)-5-methyl-2,2-diphenylhexanamide

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ327795A3 (en) * 1993-06-14 1996-08-14 Pfizer Secondary amines
EP0801060A1 (en) * 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
US5859044A (en) * 1996-07-31 1999-01-12 Pfizer Inc. β-adrenergic agonists

Also Published As

Publication number Publication date
UY28013A1 (es) 2004-04-30
TW200424171A (en) 2004-11-16
KR20050047552A (ko) 2005-05-20
DE60320439D1 (de) 2008-05-29
ECSP055780A (es) 2005-08-11
MXPA05003866A (es) 2005-06-22
EP1556034A1 (en) 2005-07-27
PL376396A1 (en) 2005-12-27
CA2499314C (en) 2010-08-24
CA2499314A1 (en) 2004-04-22
MA27452A1 (fr) 2005-07-01
NO20051406L (no) 2005-04-22
EA200500618A1 (ru) 2005-12-29
ES2302938T3 (es) 2008-08-01
IS7751A (is) 2005-03-17
WO2004032921A1 (en) 2004-04-22
PE20040775A1 (es) 2004-12-10
AR041566A1 (es) 2005-05-18
DE60320439T2 (de) 2009-05-20
BR0315234A (pt) 2005-08-23
OA12938A (en) 2006-10-13
ATE392206T1 (de) 2008-05-15
CO5550421A2 (es) 2005-08-31
JP4490911B2 (ja) 2010-06-30
AU2003269316A1 (en) 2004-05-04
JP2006511596A (ja) 2006-04-06
EP1556034B1 (en) 2008-04-16
PA8586001A1 (es) 2005-02-04

Similar Documents

Publication Publication Date Title
AP2005003283A0 (en) Indole derivatives useful for the treatment os diseases
GB0312832D0 (en) 2-amino-pyridine derivatives useful for the treatment of diseases
SI1656346T1 (sl) 1,2,3,4-tetrasubstituiran indol za zdravljenje respiratornih bolezni
IL189657A (en) Process for the preparation of n-phenyl-2-pyrimidine-amine derivatives
HK1087103A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
AU2003249244A1 (en) Methods for the treatment of neoplasms
NO20052894D0 (no) 4-tetrazolyl-4-fenylpiperidin-derivater for behandling av smerte
AP2006003671A0 (en) Sulfonamide derivatives for the treatment of diseases
AP2006003669A0 (en) Sulfonamide derivatives for the treatment of diseases
PL374401A1 (en) 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
PL1685125T3 (pl) Pochodne pirrolowe użyteczne do leczenia chorób proliferacyjnych
SI1487828T1 (sl) Morfolinil-sečninski derivati za uporabo pri zdravljenu vnetnih bolezni
HK1080859A1 (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
GB0225379D0 (en) Therapeutic proline derivatives
EG24959A (en) Indoles useful in the treatment of androgenreceptor related diseases.
AU2003223780A1 (en) Treatment for pompe disease
IL165137A0 (en) Process for the preparation of thioalkylamine derivatives
HK1059782A1 (en) Indole derivatives useful for the treatment of cnsdisorders
AU2003260942A8 (en) A process for the preparation of oxindole derivatives
AU2003296242A1 (en) Thia-epothilone derivatives for the treatment of cancer
GB0201025D0 (en) The treatment of degenerative diseases
GB0209254D0 (en) Preparation for the relief of disease
AU2003274885A1 (en) Phenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatment of pain or gastrointestinal disorders
AU2003297912A1 (en) Methods for screening compounds for use in the treatment of disease